| Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities CM Gay, CA Stewart, EM Park, L Diao, SM Groves, S Heeke, BY Nabet, ... Cancer cell 39 (3), 346-360. e7, 2021 | 715 | 2021 |
| Structure-based classification predicts drug response in EGFR-mutant NSCLC JP Robichaux, X Le, RSK Vijayan, JK Hicks, S Heeke, YY Elamin, HY Lin, ... Nature 597 (7878), 732-737, 2021 | 327 | 2021 |
| Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases JCH Yang, M Schuler, S Popat, S Miura, S Heeke, K Park, A Märten, ... Journal of Thoracic Oncology 15 (5), 803-815, 2020 | 263 | 2020 |
| Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? P Hofman, S Heeke, C Alix-Panabières, K Pantel Annals of Oncology 30 (9), 1448-1459, 2019 | 192 | 2019 |
| Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions Z Megyesfalvi, CM Gay, H Popper, R Pirker, G Ostoros, S Heeke, C Lang, ... CA: a cancer journal for clinicians 73 (6), 620-652, 2023 | 169 | 2023 |
| Never travel alone: the crosstalk of circulating tumor cells and the blood microenvironment S Heeke, B Mograbi, C Alix-Panabières, P Hofman Cells 8 (7), 714, 2019 | 132 | 2019 |
| Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not? S Heeke, P Hofman Translational lung cancer research 7 (6), 631, 2018 | 92 | 2018 |
| Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors L Berland, S Heeke, O Humbert, A Macocco, E Long-Mira, S Lassalle, ... Journal of thoracic disease 11 (Suppl 1), S71, 2019 | 87 | 2019 |
| Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity YY Elamin, JP Robichaux, BW Carter, M Altan, H Tran, DL Gibbons, ... Cancer Cell 40 (7), 754-767. e6, 2022 | 83 | 2022 |
| Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer M Ilie, C Butori, S Lassalle, S Heeke, N Piton, JC Sabourin, V Tanga, ... Oncotarget 8 (61), 103055, 2017 | 59 | 2017 |
| CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance MB Nilsson, Y Yang, S Heeke, SA Patel, A Poteete, H Udagawa, ... Cancer Cell 41 (2), 340-355. e6, 2023 | 57 | 2023 |
| Alternative splicing of P2RX7 pre-messenger RNA in health and diseases: Myth or reality? J Benzaquen, S Heeke, SJ dit Hreich, L Douguet, CH Marquette, ... biomedical journal 42 (3), 141-154, 2019 | 49 | 2019 |
| Multicenter evaluation of a novel ROS1 immunohistochemistry assay (SP384) for detection of ROS1 rearrangements in a large cohort of lung adenocarcinoma patients V Hofman, I Rouquette, E Long-Mira, N Piton, E Chamorey, S Heeke, ... Journal of Thoracic Oncology 14 (7), 1204-1212, 2019 | 46 | 2019 |
| Lung cancer models reveal severe acute respiratory syndrome coronavirus 2–induced epithelial-to-mesenchymal transition contributes to coronavirus disease 2019 pathophysiology CA Stewart, CM Gay, K Ramkumar, KR Cargill, RJ Cardnell, MB Nilsson, ... Journal of Thoracic Oncology 16 (11), 1821-1839, 2021 | 44 | 2021 |
| The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas B Mograbi, S Heeke, P Hofman Diagnostics 11 (2), 196, 2021 | 41 | 2021 |
| SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models CA Stewart, CM Gay, K Ramkumar, KR Cargill, RJ Cardnell, MB Nilsson, ... | 38 | 2020 |
| Salmonella utilizes zinc to subvert antimicrobial host defense of macrophages via modulation of NF-κB signaling A Wu, P Tymoszuk, D Haschka, S Heeke, S Dichtl, V Petzer, M Seifert, ... Infection and immunity 85 (12), 10.1128/iai. 00418-17, 2017 | 36 | 2017 |
| In-house implementation of tumor mutational burden testing to predict durable clinical benefit in non-small cell lung cancer and melanoma patients S Heeke, J Benzaquen, E Long-Mira, B Audelan, V Lespinet, O Bordone, ... Cancers 11 (9), 1271, 2019 | 35 | 2019 |
| Tumor-and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes S Heeke, CM Gay, MR Estecio, H Tran, BB Morris, B Zhang, X Tang, ... Cancer cell 42 (2), 225-237. e5, 2024 | 34 | 2024 |
| P2RX7B is a new theranostic marker for lung adenocarcinoma patients J Benzaquen, SJD Hreich, S Heeke, T Juhel, S Lalvee, S Bauwens, ... Theranostics 10 (24), 10849, 2020 | 33 | 2020 |